Bear Stearns gives Roche outperform rating

Roche was rated at outperform by Bear Stearns analyst Alexandra Hauber following the company's oncology day. While no major new information was released, concerns about risks such as competition and pricing were addressed, according to the analyst. Upcoming key events for the company include phase 3 results for and first-half results for 2006. Shares of the Basel, Switzerland-based pharmaceutical company were up CHF 1.20, or 0.63%, at CHF 192.40 on volume of 2,378,868 shares versus the three-month running average of 2,167,930 shares. (VTX: ROG)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.